Regulatory T cells (T-regs) are major drivers behind immunosuppressive mechanisms and present a major hurdle for cancer therapy. T-regs are characterized by a high expression of CD25, which is a... Show moreRegulatory T cells (T-regs) are major drivers behind immunosuppressive mechanisms and present a major hurdle for cancer therapy. T-regs are characterized by a high expression of CD25, which is a potentially valuable target for T-reg depletion to alleviate immune suppression. The preclinical anti-CD25 (alpha CD25) antibody, clone PC-61, has met with modest anti-tumor activity due to its capacity to clear T-regs from the circulation and lymph nodes, but not those that reside in the tumor. The optimization of the Fc domain of this antibody clone has been shown to enhance the intratumoral T-reg depletion capacity. Here, we generated a stable cell line that produced optimized recombinant T-reg-depleting antibodies. A genome engineering strategy in which CRISPR-Cas9 was combined with homology-directed repair (CRISPR-HDR) was utilized to optimize the Fc domain of the hybridoma PC-61 for effector functions by switching it from its original rat IgG1 to a mouse IgG2a isotype. In a syngeneic tumor mouse model, the resulting alpha CD25-m2a (mouse IgG2a isotype) antibody mediated the effective depletion of tumor-resident T-regs, leading to a high effector T cell (T-eff) to T-reg ratio. Moreover, a combination of alpha CD25-m2a and an alpha PD-L1 treatment augmented tumor eradication in mice, demonstrating the potential for alpha CD25 as a cancer immunotherapy. Show less
